Oncolytics Biotech Presents Pancreatic Cancer Data at ASCO 2025 Annual Meeting

Oncolytics Biotech will present new data from Cohort 1 of the GOBLET study at ASCO 2025, highlighting pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma. The study demonstrates pelareorep's potential to activate immune responses in pancreatic cancer patients, supporting combination therapies for one of the deadliest and hardest-to-treat cancers.

Oncolytics Biotech Inc. (NASDAQ: ONCY) will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, scheduled for June 2, 2025, will highlight the anti-tumor activity of pelareorep in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer [1].

The data will demonstrate how pelareorep activates immune responses in pancreatic cancer patients. According to Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech, pelareorep has shown encouraging results in multiple studies by engaging the immune system to attack pancreatic cancer tumors, potentially improving outcomes for patients with this hard-to-treat cancer [1].

The GOBLET study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors, conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The primary endpoints of the study are objective response rate (ORR) and/or disease control rate assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers [1].

Oncolytics Biotech is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promoting an inflamed tumor phenotype, turning "cold" tumors "hot" through innate and adaptive immune responses to treat a variety of cancers [1].

The presentation, titled 'Role of pelareorep in activating anti-tumor immunity in PDAC,' will be delivered as a poster in the Developmental Therapeutics – Immunotherapy session on June 2, 2025. The abstract will be published on the ASCO website at 5:00 p.m. ET on May 22, 2025 [1].

This development underscores Oncolytics Biotech's commitment to advancing immunotherapy for oncology, particularly in pancreatic cancer, where few effective treatments exist. The company is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [1].

References:
[1] https://www.prnewswire.com/news-releases/oncolytics-biotech-to-showcase-new-pancreatic-cancer-data-at-asco-highlighting-pelareoreps-tumor-fighting-mechanism-of-action-302437172.html